Inhaled nitric oxide in pediatric cardiac surgery.
Kawakami
Hiromasa
H
Department of Anesthesia and Critical Care, Massachusetts General Hospital, Boston 02114, USA.
Ichinose
Fumito
F
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000280:Administration, Inhalation; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006330:Heart Defects, Congenital / Q000601:surgery; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000517:prevention & control; D007223:Infant; D007231:Infant, Newborn; D009569:Nitric Oxide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011183:Postoperative Complications / Q000517:prevention & control; D014664:Vasodilation / Q000187:drug effects
D001993:Bronchodilator Agents; D010726:Phosphodiesterase Inhibitors; D009569:Nitric Oxide; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human